See more : Daseke, Inc. Warrant (DSKEW) Income Statement Analysis – Financial Results
Complete financial analysis of MDxHealth SA (MDXH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MDxHealth SA, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Rupa & Company Limited (RUPA.NS) Income Statement Analysis – Financial Results
- JGC Holdings Corporation (1963.T) Income Statement Analysis – Financial Results
- Come Sure Group (Holdings) Limited (0794.HK) Income Statement Analysis – Financial Results
- Peoples Bancorp of North Carolina, Inc. (PEBK) Income Statement Analysis – Financial Results
- All for One Group SE (A1OS.DE) Income Statement Analysis – Financial Results
MDxHealth SA (MDXH)
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.19M | 37.05M | 22.24M | 18.37M | 11.79M | 28.34M | 40.51M | 29.87M | 17.47M | 11.48M | 7.55M | 4.92M | 3.48M | 3.37M | 3.65M | 4.21M | 3.85M | 3.66M | 3.65M | 525.97K |
| Cost of Revenue | 26.26M | 17.84M | 11.83M | 10.52M | 11.93M | 11.65M | 10.20M | 10.10M | 6.91M | 6.45M | 5.79M | 1.19M | 344.76K | 492.09K | 256.46K | 338.28K | 656.10K | 72.59K | 135.02K | 12.20K |
| Gross Profit | 43.93M | 19.22M | 10.41M | 7.85M | -144.00K | 16.69M | 30.31M | 19.76M | 10.56M | 5.03M | 1.76M | 3.72M | 3.14M | 2.88M | 3.39M | 3.87M | 3.19M | 3.58M | 3.51M | 513.77K |
| Gross Profit Ratio | 62.58% | 51.87% | 46.82% | 42.72% | -1.22% | 58.88% | 74.81% | 66.17% | 60.47% | 43.78% | 23.31% | 75.72% | 90.10% | 85.41% | 92.97% | 91.96% | 82.96% | 98.02% | 96.30% | 97.68% |
| Research & Development | 6.38M | 7.56M | 6.67M | 4.54M | 9.00M | 1.81M | 1.83M | -332.00K | 2.10M | 742.00K | 1.58M | 3.29M | 6.23M | 9.06M | 18.75M | 15.31M | 15.60M | 11.41M | 6.85M | 6.23M |
| General & Administrative | 23.01M | 23.54M | 5.07M | 4.15M | 5.68M | 6.19M | 5.35M | 3.95M | 2.97M | 2.50M | 1.86M | 1.80M | 6.20M | 4.98M | 5.75M | 4.33M | 3.59M | 2.50M | 1.80M | 1.40M |
| Selling & Marketing | 36.92M | 26.58M | 2.59M | 2.31M | 4.43M | 9.07M | 8.15M | 7.61M | 6.02M | 4.91M | 2.50M | 2.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.93M | 50.12M | 7.65M | 6.46M | 10.10M | 15.26M | 13.51M | 11.56M | 8.99M | 7.40M | 4.36M | 4.75M | 6.20M | 4.98M | 5.75M | 4.33M | 3.59M | 2.50M | 1.80M | 1.40M |
| Other Expenses | 4.96M | -559.00K | 22.93M | 23.97M | 23.92M | 31.71M | 27.25M | 21.39M | 13.85M | 12.22M | 11.90M | 7.46M | -93.32K | -33.25K | 0.00 | 1.39K | -77.27K | -242.84K | -72.25K | -67.78K |
| Operating Expenses | 71.26M | 57.12M | 37.25M | 34.97M | 43.03M | 48.78M | 42.58M | 32.61M | 24.94M | 20.37M | 17.83M | 15.50M | 12.34M | 14.01M | 24.50M | 19.64M | 19.25M | 14.18M | 8.72M | 7.70M |
| Cost & Expenses | 97.52M | 74.95M | 49.08M | 45.50M | 54.95M | 60.44M | 52.78M | 42.71M | 31.85M | 26.82M | 23.63M | 16.70M | 12.68M | 14.50M | 24.76M | 19.98M | 19.91M | 14.25M | 8.86M | 7.71M |
| Interest Income | 1.09M | 125.00K | 11.00K | 4.00K | 10.00K | 21.00K | 0.00 | 6.00K | 13.00K | 14.00K | 16.00K | 87.29K | 277.36K | 295.25K | 644.74K | 1.59M | 1.53M | 868.43K | 138.57K | 146.40K |
| Interest Expense | 5.58M | 6.14M | 1.88M | 1.35M | 318.00K | 82.00K | 0.00 | 0.00 | 99.00K | 23.00K | 20.00K | 357.08K | 82.95K | 113.05K | 28.65K | 12.53K | 1.61M | 1.11M | 210.82K | 214.19K |
| Depreciation & Amortization | 6.86M | 4.91M | 3.04M | 3.33M | 3.42M | 2.94M | 2.21M | 1.72M | 881.00K | 333.00K | 418.00K | 527.68K | 397.90K | 462.83K | 3.29M | 1.40M | 839.81K | 497.56K | 280.70K | 325.34K |
| EBITDA | -30.47M | -36.39M | -23.99M | -23.79M | -39.74M | -29.47M | -10.19M | -11.57M | -13.50M | -14.88M | -15.59M | -9.80M | -9.22M | -10.37M | -16.66M | -13.43M | -12.86M | -8.77M | -4.93M | -6.86M |
| EBITDA Ratio | -43.41% | -89.03% | -107.46% | -130.55% | -338.88% | -104.00% | -24.88% | -37.25% | -77.29% | -130.33% | -203.20% | -228.77% | -244.73% | -307.41% | -470.29% | -303.54% | -395.27% | -276.04% | -135.09% | -1,304.64% |
| Operating Income | -27.33M | -37.90M | -26.84M | -27.12M | -43.17M | -32.10M | -12.27M | -12.85M | -14.38M | -15.34M | -16.07M | -11.78M | -9.20M | -11.13M | -21.11M | -15.77M | -16.00M | -10.35M | -5.14M | -7.12M |
| Operating Income Ratio | -38.93% | -102.28% | -120.69% | -147.63% | -366.30% | -113.27% | -30.30% | -43.01% | -82.34% | -133.65% | -212.75% | -239.50% | -264.12% | -329.89% | -578.14% | -374.54% | -415.41% | -283.00% | -140.80% | -1,353.61% |
| Total Other Income/Expenses | -15.77M | -6.14M | -2.16M | -1.54M | -506.00K | -393.00K | -127.00K | -441.00K | -91.00K | 86.00K | -104.00K | -89.00K | 209.00K | 182.21K | 616.08K | 853.66K | 1.45M | 625.59K | -180.88K | 78.62K |
| Income Before Tax | -43.10M | -44.04M | -29.00M | -28.66M | -43.68M | -32.49M | -12.40M | -13.29M | -14.47M | -15.26M | -16.18M | -11.87M | -9.00M | -10.94M | -20.49M | -14.19M | -14.54M | -9.72M | -5.07M | -7.04M |
| Income Before Tax Ratio | -61.40% | -118.86% | -130.41% | -156.01% | -370.60% | -114.66% | -30.61% | -44.49% | -82.86% | -132.90% | -214.12% | -241.36% | -258.54% | -324.49% | -561.26% | -337.04% | -377.70% | -265.90% | -138.98% | -1,338.66% |
| Income Tax Expense | 1.00K | 6.14M | 1.88M | 1.35M | -575.00K | -41.00K | -113.00K | -113.00K | 86.00K | 9.00K | 4.00K | 91.25K | -194.41K | 31.92K | -616.08K | -1.58M | -1.61M | -1.11M | -210.82K | -214.19K |
| Net Income | -43.10M | -50.19M | -30.88M | -30.01M | -43.10M | -32.45M | -12.29M | -13.17M | -14.47M | -15.26M | -16.18M | -11.87M | -9.00M | -10.98M | -20.49M | -14.19M | -14.54M | -9.72M | -5.07M | -7.04M |
| Net Income Ratio | -61.40% | -135.45% | -138.84% | -163.33% | -365.72% | -114.51% | -30.33% | -44.11% | -82.86% | -132.90% | -214.12% | -241.36% | -258.54% | -325.43% | -561.26% | -337.04% | -377.70% | -265.90% | -138.98% | -1,338.66% |
| EPS | -1.66 | -3.16 | -2.53 | -3.61 | -6.89 | -5.63 | -2.46 | -2.86 | -3.51 | -4.39 | -5.38 | -5.38 | -5.23 | -8.32 | -15.55 | -11.98 | -13.46 | -11.33 | -11.10 | -18.76 |
| EPS Diluted | -1.66 | -3.16 | -2.53 | -3.61 | -6.89 | -5.63 | -2.46 | -2.86 | -3.51 | -4.39 | -5.38 | -5.38 | -5.23 | -8.32 | -15.55 | -11.98 | -13.46 | -11.33 | -11.10 | -18.76 |
| Weighted Avg Shares Out | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.99M | 4.61M | 4.13M | 3.48M | 3.00M | 2.21M | 1.72M | 1.32M | 1.32M | 1.18M | 1.08M | 857.92K | 456.88K | 375.28K |
| Weighted Avg Shares Out (Dil) | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.99M | 4.61M | 4.13M | 3.48M | 3.00M | 2.21M | 1.72M | 1.32M | 1.32M | 1.18M | 1.08M | 857.92K | 456.88K | 375.28K |
Mdxhealth Appoints Sanford J. Siegel, M.D.
Mdxhealth Appoints Sanford J. Siegel, M.D.
Mdxhealth to Present at Upcoming Investor Conferences
Mdxhealth to Present at Upcoming Investor Conferences IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 (GlobeNewswire) – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the...
MDxHealth SA (MDXH) Q1 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q1 2024 Results Conference Call May 1, 2024 8:30 AM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Jason Bednar - Piper Sandler Mark Massaro...
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 million Increasing 2024 revenue guidance to $83-85 million, previously $79-81 million Conference call with Q&A today at 08:30 AM ET / 14:30...
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a...
MDxHealth SA (MDXH) Q4 2023 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Jason Bednar...
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42% 2023 gross margin expanded by 10.7 percentage points over prior year Conference call with Q&A today at 4:30...
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
Mdxhealth Announces Resignation of Board Member
Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the...
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – January 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today reported preliminary fourth quarter...
Source: https://incomestatements.info
Category: Stock Reports